after covering last week at $48.85 from my first short position at $49.51 ..... kool-aid will run dry in 2012, especially with EPS guidance (mid-point) of .92, or an astronomical P/E of 54 and a business model that obviously needed an adjustment. Wayyyyy too much risk in going long this name. With EPS flat YOY 2012 to 2011, no wayyyyyy this stock gets a multiple of 54, even with 30% revenue growth. Give it a P/E of 30 to match its revenue growth rate or a stock price of $27.60, but without 30% growth in EPS, I don't know how you'd even assign this a 30 P/E. I'm still LOL at Oppenheimer's upgrading of the stock with a $34 price target.
Might want to look indept on what they do - they are leading in web-based cloud EMR software. To my knowledge no other software vendor really competes...example would be to compare Googe to Microsoft....not much to compare. They are very different than Mckesson, Allscripts, etc - to my knowledge. Anyone who really understands their business please comment. I don't think I would short this based on the software strategy they have embraced....web-based. Of course, I could be wrong.